Elements of cancer immunity and the cancer–immune set point
The DOI matches its Crossref record; 122 of the 122 references it cites were found in a registry or an index.
Abstract
Immunotherapy is proving to be an effective therapeutic approach in a variety of cancers. But despite the clinical success of antibodies against the immune regulators CTLA4 and PD-L1/PD-1, only a subset of people exhibit durable responses, suggesting that a broader view of cancer immunity is required. Immunity is influenced by a complex set of tumour, host and environmental factors that govern the strength and timing of the anticancer response. Clinical studies are beginning to define these factors as immune profiles that can predict responses to immunotherapy. In the context of the cancer-immunity cycle, such factors combine to represent the inherent immunological status - or 'cancer-immune set point' - of an individual.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This model effectively identifies two main clusters resembling the Immune-Inflamed and Immune-Desert phenotypes42–44”
From Predicting the tumor microenvironment composition and immunotherapy response in non-small cell lung cancer from digital histopathology images (2024) · cites this paper as [43]
In the citing paper
“Tumor-infiltrating lymphocytes (TILs) have been proven to be associated with immunotherapy response 245, OS, and PFS 246.”
From Artificial intelligence in pancreatic cancer (2022) · cites this paper as [245]
In the citing paper
“The microbiota influences the cancer-immune set point, which is the threshold beyond which an immune response can be elicited in a given individual.”
From Melanoma and microbiota: Current understanding and future directions (2024) · cites this paper as [11]
In the citing paper
“Recently, it has been demonstrated that the efficacy of the treatment with immune checkpoint inhibitors can be influenced by the composition of the host gut microbiota (176).”
From Immunosenescence and Its Hallmarks: How to Oppose Aging Strategically? A Review of Potential Options for Therapeutic Intervention (2019) · cites this paper as [176]
In the citing paper
“a variety of clinically relevant anticancer interventions including conventional chemotherapeutics (Galluzzi et al., 2020a), radiation therapy (RT) (Rodriguez-Ruiz et al., 2020), and targeted anticancer agents (see main text) have been shown to elicit bona fide ICD and hence jumpstart the cancer-immunity cycle (Chen and Mellman, 2017) in preclinical tumor models.”
From Immunomodulation by targeted anticancer agents (2021) · cites this paper as Chen and Mellman, 2017
9 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Safety and activity of anti-PD-L1 antibody in patients with advanced cancer
Brahmer, J. R., Tykodi, S. S., Chow, L. Q. M., Hwu, W.-J., Topalian, S. L., Hwu, P., Drake, C. G., Camacho, L. H., Kauh, J., Odunsi, K., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200694 · Cited by 7,945
Mutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802
Oncology meets immunology: the cancer-immunity cycle.
Chen, D. S., & Mellman, I. (2013) · Immunity · doi:10.1016/j.immuni.2013.07.012 · Cited by 6,929
Self-citation
Cited by
Items 201–300 of 1,026
Xiao, M., Zhang, J., Chen, W., & Chen, W. (2018) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-018-0815-2 · Cited by 256
Gut microbiome and cancer immunotherapy
Li, W., Deng, Y., Chu, Q., & Zhang, P. (2019) · Cancer Letters · doi:10.1016/j.canlet.2019.01.015 · Cited by 253
Host tissue determinants of tumour immunity
Salmon, H., Remark, R., Gnjatic, S., & Merad, M. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0125-9 · Cited by 253
Huber, V., Vallacchi, V., Fleming, V., Hu, X., Cova, A., Dugo, M., Shahaj, E., Sulsenti, R., Vergani, E., Filipazzi, P., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci98060 · Cited by 250
Mechanisms of metastatic colorectal cancer
Cañellas-Socias, A., Sancho, E., & Batlle, E. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00934-z · Cited by 249
“By contrast, replacement HGP features a sparse immune cell presence 122,127–129 , implying this type of metastasis might fall into the immune-desert category 130 (Fig.”
Zhang, Z., Tang, H., Chen, P., Xie, H., & Tao, Y. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0074-5 · Cited by 251
Fusobacterium nucleatum facilitates anti-PD-1 therapy in microsatellite stable colorectal cancer
Wang, X., Fang, Y., Liang, W., Wong, C. C., Qin, H., Gao, Y., Liang, M., Song, L., Zhang, Y., Fan, M., et al. (2024) · Cancer Cell · doi:10.1016/j.ccell.2024.08.019 · Cited by 247
Stanczak, M. A., Rodrigues Mantuano, N., Kirchhammer, N., Sanin, D. E., Jacob, F., Coelho, R., Everest-Dass, A. V., Wang, J., Trefny, M. P., Monaco, G., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abj1270 · Cited by 243
Elkrief, A., Derosa, L., Kroemer, G., Zitvogel, L., & Routy, B. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz206 · Cited by 246
Messaoudene, M., Pidgeon, R., Richard, C., Ponce, M., Diop, K., Benlaifaoui, M., Nolin-Lapalme, A., Cauchois, F., Malo, J., Belkaid, W., et al. (2022) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-0808 · Cited by 250
“Recent metagenomic sequencing studies coupled with experiments in germ-free (GF) mice have revealed that the gut microbiome serves as another key mediator of this cancer-immune set point (5, 6).”
BackgroundCircular RNA cancer vaccines drive immunity in hard-to-treat malignancies
Li, H., Peng, K., Yang, K., Ma, W., Qi, S., Yu, X., He, J., Lin, X., & Yu, G. (2022) · Theranostics · doi:10.7150/thno.77350 · Cited by 241
“However, attempts to use them in “immune-desert” and “immuneexcluded” solid tumors remains unsatisfactory results, mainly due to the immunosuppressive tumor microenvironment [9-11].”
BackgroundCombined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors
Peyraud, F., & Italiano, A. (2020) · Cancers · doi:10.3390/cancers12061502 · Cited by 242
“The subsequent antitumor immune process against neoantigens relies on several steps, including the release and presentation of cancer antigens by antigen-presenting cells (APC), priming and activation of T cells, trafficking and infiltration of T cells, and recognizing and killing cancer cells [18].”
BackgroundTeng, F., Meng, X., Kong, L., & Yu, J. (2018) · Cancer Letters · doi:10.1016/j.canlet.2017.11.014 · Cited by 243
Hot and cold tumors: Immunological features and the therapeutic strategies
Wang, L., Geng, H., Liu, Y., Liu, L., Chen, Y., Wu, F., Liu, Z., Ling, S., Wang, Y., & Zhou, L. (2023) · MedComm · doi:10.1002/mco2.343 · Cited by 241
Pharmacological targeting of MYC-regulated IRE1/XBP1 pathway suppresses MYC-driven breast cancer
Zhao, N., Cao, J., Xu, L., Tang, Q., Dobrolecki, L. E., Lv, X., Talukdar, M., Lu, Y., Wang, X., Hu, D. Z., et al. (2018) · Journal of Clinical Investigation · doi:10.1172/jci95873 · Cited by 239
Prognostic and predictive biomarkers for immunotherapy in advanced renal cell carcinoma
Rosellini, M., Marchetti, A., Mollica, V., Rizzo, A., Santoni, M., & Massari, F. (2023) · Nature Reviews Urology · doi:10.1038/s41585-022-00676-0 · Cited by 240
“were shown in three different studies: the tumour immune profiles proposed by Chen et al.(134) (blue), and the subgroups described by Beuselinck et al.”
MethodWNT Signaling in Cancer Immunosurveillance
Galluzzi, L., Spranger, S., Fuchs, E., & López-Soto, A. (2019) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.08.005 · Cited by 239
Immune checkpoints in the tumor microenvironment
Toor, S. M., Sasidharan Nair, V., Decock, J., & Elkord, E. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2019.06.021 · Cited by 236
Dendritic cells direct circadian anti-tumour immune responses
Wang, C., Barnoud, C., Cenerenti, M., Sun, M., Caffa, I., Kizil, B., Bill, R., Liu, Y., Pick, R., Garnier, L., et al. (2023) · Nature · doi:10.1038/s41586-022-05605-0 · Cited by 238
Hallmarks of response to immune checkpoint blockade
Cogdill, A. P., Andrews, M. C., & Wargo, J. A. (2017) · British Journal of Cancer · doi:10.1038/bjc.2017.136 · Cited by 238
Wang, Z., Ye, Q., Yu, S., & Akhavan, B. (2023) · Advanced Healthcare Materials · doi:10.1002/adhm.202300105 · Cited by 236
Fibronectin in Cancer: Friend or Foe
Lin, T.-C., Yang, C.-H., Cheng, L.-H., Chang, W.-T., Lin, Y.-R., & Cheng, H.-C. (2019) · Cells · doi:10.3390/cells9010027 · Cited by 234
“CTCs make an adventurous journey en route to distant organs with various risky environmental stresses, including anoikis due to a loss of anchorage-dependent cell growth signal stimuli [260], mechanical pressures due to shear stresses and cell deformation within blood vessels of smaller diameter [257], a normal immuno…”
BackgroundKowanetz, M., Zou, W., Gettinger, S. N., Koeppen, H., Kockx, M., Schmid, P., Kadel, E. E., Wistuba, I., Chaft, J., Rizvi, N. A., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1802166115 · Cited by 235
“It is important to point out, however, that these stromally invested, desmoplastic tumors appear histologically distinct from the “immune excluded” phenotype seen often in indications, such as metastatic urothelial bladder cancer (mUC), colorectal cancer, and others (11, 37, 38).”
BackgroundSelf-citationChen, H., Yao, J., Bao, R., Dong, Y., Zhang, T., Du, Y., Wang, G., Ni, D., Xun, Z., Niu, X., et al. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01322-w · Cited by 234
Li, Y., Su, Z., Zhao, W., Zhang, X., Momin, N., Zhang, C., Wittrup, K. D., Dong, Y., Irvine, D. J., & Weiss, R. (2020) · Nature Cancer · doi:10.1038/s43018-020-0095-6 · Cited by 233
Yi, M., Zhang, J., Li, A., Niu, M., Yan, Y., Jiao, Y., Luo, S., Zhou, P., & Wu, K. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01045-x · Cited by 233
Preclinical and clinical development of neoantigen vaccines
Li, L., Goedegebuure, S. P., & Gillanders, W. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx681 · Cited by 232
Zhang, X., Shi, M., Chen, T., & Zhang, B. (2020) · Molecular Therapy Nucleic Acids · doi:10.1016/j.omtn.2020.08.030 · Cited by 232
“Multiple studies have shown that the immune system may have favorable and adverse outcomes, which could be exhibited in the form of pro-tumor or anti-tumor activity, as observed in our analysis.(13,16) As depicted in Figure 2E, gene cluster C showed an escalated stromal component infiltration and immunosuppression-ass…”
BackgroundResultInfluentialUncovering the mode of action of engineered T cells in patient cancer organoids
Dekkers, J. F., Alieva, M., Cleven, A., Keramati, F., Wezenaar, A. K. L., van Vliet, E. J., Puschhof, J., Brazda, P., Johanna, I., Meringa, A. D., et al. (2023) · Nature Biotechnology · doi:10.1038/s41587-022-01397-w · Cited by 227
Antitumor Benefits of Antiviral Immunity: An Underappreciated Aspect of Oncolytic Virotherapies
Gujar, S., Pol, J. G., Kim, Y., Lee, P. W., & Kroemer, G. (2018) · Trends in Immunology · doi:10.1016/j.it.2017.11.006 · Cited by 231
TIGIT-CD226-PVR axis: advancing immune checkpoint blockade for cancer immunotherapy
Chiang, E. Y., & Mellman, I. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-004711 · Cited by 226
Self-citationSeo, Y. D., Jiang, X., Sullivan, K. M., Jalikis, F. G., Smythe, K. S., Abbasi, A., Vignali, M., Park, J. O., Daniel, S. K., Pollack, S. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-0081 · Cited by 227
“A recent model of cancer immune set points suggests that, unlike an immune desert with no priming of innate immunity and complete tolerance, or a truly inflamed tumor with varied reactive elements, the human PDA microenvironment is one of immune exclusion, with stromal interactions blocking previously primed immune el…”
BackgroundChong, W., Shang, L., Liu, J., Fang, Z., Du, F., Wu, H., Liu, Y., Wang, Z., Chen, Y., Jia, S., et al. (2021) · Theranostics · doi:10.7150/thno.52717 · Cited by 229
“Current studies also proposed the novel concept of ‘immune contexture’, which classified CC tumors into three major immune coordination profiles (hot, excluded and cold) and represented different TME characteristics and treatment options [23-25].”
Trial watch: chemotherapy-induced immunogenic cell death in immuno-oncology
Vanmeerbeek, I., Sprooten, J., De Ruysscher, D., Tejpar, S., Vandenberghe, P., Fucikova, J., Spisek, R., Zitvogel, L., Kroemer, G., Galluzzi, L., et al. (2020) · OncoImmunology · doi:10.1080/2162402x.2019.1703449 · Cited by 227
Wang, G., Kang, X., Chen, K. S., Jehng, T., Jones, L., Chen, J., Huang, X. F., & Chen, S.-Y. (2020) · Nature Communications · doi:10.1038/s41467-020-15229-5 · Cited by 226
Targeting lysosomes in human disease: from basic research to clinical applications
Cao, M., Luo, X., Wu, K., & He, X. (2021) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00778-y · Cited by 225
The role of cancer-derived microRNAs in cancer immune escape
Yi, M., Xu, L., Jiao, Y., Luo, S., Li, A., & Wu, K. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00848-8 · Cited by 221
Functions of autophagy in the tumor microenvironment and cancer metastasis
Mowers, E. E., Sharifi, M. N., & Macleod, K. F. (2018) · The FEBS Journal · doi:10.1111/febs.14388 · Cited by 221
Vadakekolathu, J., Minden, M. D., Hood, T., Church, S. E., Reeder, S., Altmann, H., Sullivan, A. H., Viboch, E. J., Patel, T., Ibrahimova, N., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aaz0463 · Cited by 216
Wienke, J., Dierselhuis, M. P., Tytgat, G. A. M., Künkele, A., Nierkens, S., & Molenaar, J. J. (2021) · European Journal of Cancer · doi:10.1016/j.ejca.2020.11.014 · Cited by 217
“Tumour immunogenicity Neuroblastoma tumours are lowly immunogenic due to their low mutational burden, which is associated with a low generation of neo-antigens [15,54,55].”
BackgroundPersonalized detection of circling exosomal PD-L1 based on Fe3O4@TiO2 isolation and SERS immunoassay
Pang, Y., Shi, J., Yang, X., Wang, C., Sun, Z., & Xiao, R. (2020) · Biosensors and Bioelectronics · doi:10.1016/j.bios.2019.111800 · Cited by 215
Targeting focal adhesion kinase in cancer cells and the tumor microenvironment
Murphy, J. M., Rodriguez, Y. A. R., Jeong, K., Ahn, E.-Y. E., & Lim, S.-T. S. (2020) · Experimental & Molecular Medicine · doi:10.1038/s12276-020-0447-4 · Cited by 212
Taber, A., Christensen, E., Lamy, P., Nordentoft, I., Prip, F., Lindskrog, S. V., Birkenkamp-Demtröder, K., Okholm, T. L. H., Knudsen, M., Pedersen, J. S., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-18640-0 · Cited by 213
Immunomodulation by targeted anticancer agents
Petroni, G., Buqué, A., Zitvogel, L., Kroemer, G., & Galluzzi, L. (2021) · Cancer Cell · doi:10.1016/j.ccell.2020.11.009 · Cited by 212
Fu, Q., Xu, L., Wang, Y., Jiang, Q., Liu, Z., Zhang, J., Zhou, Q., Zeng, H., Tong, S., Wang, T., et al. (2019) · European Urology · doi:10.1016/j.eururo.2018.09.030 · Cited by 211
Complementing the Cancer-Immunity Cycle
Pio, R., Ajona, D., Ortiz-Espinosa, S., Mantovani, A., & Lambris, J. D. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00774 · Cited by 211
“An effective cancer immunotherapy should be designed based on the specific resistance mechanisms underlining the rate-limiting steps in each particular patient (14, 15).”
BackgroundXu, L., Zou, C., Zhang, S., Chu, T. S. M., Zhang, Y., Chen, W., Zhao, C., Yang, L., Xu, Z., Dong, S., et al. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01307-2 · Cited by 209
“In addition to the genetic differences of the tumor itself, the immune systems of different patients are dissimilar, which is one of the important reasons behind the differences observed in the efficacy of PD-1 inhibitors in different patients [100].”
BackgroundNeoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
Efremova, M., Finotello, F., Rieder, D., & Trajanoski, Z. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01679 · Cited by 211
“org November 2017 | Volume 8 | Article 1679 are proteins that are expressed only by germline cells and have aberrant expression in tumor cells; and (3) neoantigens, i.”
BackgroundMethodDosset, M., Vargas, T. R., Lagrange, A., Boidot, R., Végran, F., Roussey, A., Chalmin, F., Dondaine, L., Paul, C., Marie-Joseph, E. L., et al. (2018) · OncoImmunology · doi:10.1080/2162402x.2018.1433981 · Cited by 210
“The efficacy of anti-PD-1 immunotherapy is associated to the pre-existence of abundant PD1 CD8 T cells in TME.(7,10,29) We showed that Folfox promoted activated tumor-specific PD-1CCD8T cells in the TME, creating a suitable environment for the action of anti-PD-1 therapy.”
BackgroundWang, G., Xie, L., Li, B., Sang, W., Yan, J., Li, J., Tian, H., Li, W., Zhang, Z., Tian, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-25990-w · Cited by 208
Wang, S., Liang, B., Wang, W., Li, L., Feng, N., Zhao, Y., Wang, T., Yan, F., Yang, S., & Xia, X. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01408-5 · Cited by 211
“Immunotherapy is an effective therapeutic approach in cancer, of which oncolytic virotherapy is an important branch of tumor immunotherapy.(354) Briefly, oncolytic viruses (OVs) are naturally occurring or genetically engineered to preferentially replicat and selectively kill tumor cells, release TAAs, and stimulate th…”
BackgroundMu, W., Jiang, L., Shi, Y., Tunali, I., Gray, J. E., Katsoulakis, E., Tian, J., Gillies, R. J., & Schabath, M. B. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-002118 · Cited by 207
Udall, M., Rizzo, M., Kenny, J., Doherty, J., Dahm, S., Robbins, P., & Faulkner, E. (2018) · Diagnostic Pathology · doi:10.1186/s13000-018-0689-9 · Cited by 208
“It has also been theorized that different cell phenotypes/characteristics may also contribute to this variability in PD-L1 expression across cancer cells [32].”
BackgroundDesbois, M., Udyavar, A. R., Ryner, L., Kozlowski, C., Guan, Y., Dürrbaum, M., Lu, S., Fortin, J.-P., Koeppen, H., Ziai, J., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19408-2 · Cited by 208
High endothelial venules (HEVs) in immunity, inflammation and cancer
Blanchard, L., & Girard, J.-P. (2021) · Angiogenesis · doi:10.1007/s10456-021-09792-8 · Cited by 207
“Checkpoint blockade therapy with anti-PD-1 and antiCTLA-4 antibodies provides remarkable and durable responses for many patients across different types of cancer [317, 318, 320].”
BackgroundCombinations of Bevacizumab With Cancer Immunotherapy
Chen, D. S., & Hurwitz, H. (2018) · The Cancer Journal · doi:10.1097/ppo.0000000000000327 · Cited by 207
Self-citationCremasco, V., Astarita, J. L., Grauel, A. L., Keerthivasan, S., MacIsaac, K., Woodruff, M. C., Wu, M., Spel, L., Santoro, S., Amoozgar, Z., et al. (2018) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-18-0098 · Cited by 207
“This enrichment of immune cells in peritumoral stromal-dense areas has also been observed in patients with cancer and has been suggested to curtail clinical benefits of immunotherapies (36, 37, 40).”
BackgroundKim, K. H., Cho, J., Ku, B. M., Koh, J., Sun, J.-M., Lee, S.-H., Ahn, J. S., Cheon, J., Min, Y. J., Park, S.-H., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1449 · Cited by 205
Chauhan, V. P., Chen, I. X., Tong, R., Ng, M. R., Martin, J. D., Naxerova, K., Wu, M. W., Huang, P., Boucher, Y., Kohane, D. S., et al. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1819889116 · Cited by 206
“A hallmark of some nonresponsive tumors, such as desmoplastic breast cancers, is that they are rich in cancer-associated fibroblasts (CAFs) and extracellular matrix (2).”
BackgroundContext-Specific Determinants of the Immunosuppressive Tumor Microenvironment in Pancreatic Cancer
Falcomatà, C., Bärthel, S., Schneider, G., Rad, R., Schmidt-Supprian, M., & Saur, D. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-22-0876 · Cited by 203
Ni, K., Aung, T., Li, S., Fatuzzo, N., Liang, X., & Lin, W. (2019) · Chem · doi:10.1016/j.chempr.2019.05.013 · Cited by 205
RetractedMomin, N., Mehta, N. K., Bennett, N. R., Ma, L., Palmeri, J. R., Chinn, M. M., Lutz, E. A., Kang, B., Irvine, D. J., Spranger, S., et al. (2019) · Science Translational Medicine · doi:10.1126/scitranslmed.aaw2614 · Cited by 204
“In general, tumors can be prognostically classified into phenotypes including “immune desert,” “immune excluded,” or “inflamed” based on their T cell infiltration (1).”
BackgroundTreatment after progression in the era of immunotherapy
Billan, S., Kaidar-Person, O., & Gil, Z. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30328-4 · Cited by 204
Wu, Q., Qian, W., Sun, X., & Jiang, S. (2022) · Journal of Hematology & Oncology · doi:10.1186/s13045-022-01362-9 · Cited by 200
Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects
Thomas, R., Al-Khadairi, G., & Decock, J. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2020.600573 · Cited by 202
Tumor Functional Heterogeneity Unraveled by scRNA-seq Technologies
González-Silva, L., Quevedo, L., & Varela, I. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2019.11.010 · Cited by 200
Nanomaterial-Based Tumor Photothermal Immunotherapy
Xu, P., & Liang, F. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s249252 · Cited by 201
Analysis of multispectral imaging with the AstroPath platform informs efficacy of PD-1 blockade
Berry, S., Giraldo, N. A., Green, B. F., Cottrell, T. R., Stein, J. E., Engle, E. L., Xu, H., Ogurtsova, A., Roberts, C., Wang, D., et al. (2021) · Science · doi:10.1126/science.aba2609 · Cited by 199
“Degrees of surface expression of immune regulatory molecules, such as PD-1, have profound relevance to cellular functional states (15).”
Zhao, S., Ma, D., Xiao, Y., Li, X.-M., Ma, J.-L., Zhang, H., Xu, X.-L., Lv, H., Jiang, W.-H., Yang, W.-T., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2019-0982 · Cited by 197
“CD8+ T cells are a crucial component of adaptive immune system and play a major role in antitumor immunity [26].”
BackgroundYang, J., & Hu, L. (2019) · Medicinal Research Reviews · doi:10.1002/med.21530 · Cited by 190
“initial activation event and serve to establish immunologic memory, ready to stimulate a more rapid immune response upon re‐exposure to tumor cells expressing the same antigen, thereby providing durable protection against cancer.(16) As cancer mutates over time, an overwhelming number of antigens are created.”
BackgroundChen, X., Pan, X., Zhang, W., Guo, H., Cheng, S., He, Q., Yang, B., & Ding, L. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2019.09.006 · Cited by 197
Pérez-Ruiz, E., Melero, I., Kopecka, J., Sarmento-Ribeiro, A. B., García-Aranda, M., & De Las Rivas, J. (2020) · Drug Resistance Updates · doi:10.1016/j.drup.2020.100718 · Cited by 196
“For the time being, a myriad of combination clinical trials are precisely addressing the population of patients whose malignancies progress despite having received checkpoint inhibitors (Chen and Mellman, 2017).”
BackgroundAnti–PD-L1 Treatment Results in Functional Remodeling of the Macrophage Compartment
Xiong, H., Mittman, S., Rodriguez, R., Moskalenko, M., Pacheco-Sanchez, P., Yang, Y., Nickles, D., & Cubas, R. (2019) · Cancer Research · doi:10.1158/0008-5472.can-18-3208 · Cited by 197
The Immune Subtypes and Landscape of Squamous Cell Carcinoma
Li, B., Cui, Y., Nambiar, D. K., Sunwoo, J. B., & Li, R. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-4085 · Cited by 197
“However, because of its complex and dynamic nature, our understanding of the immune response in tumormicroenvironment remains incomplete (11, 12).”
BackgroundHaas, L., Elewaut, A., Gerard, C. L., Umkehrer, C., Leiendecker, L., Pedersen, M., Krecioch, I., Hoffmann, D., Novatchkova, M., Kuttke, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00221-9 · Cited by 196
Study and analysis of antitumor resistance mechanism of PD1/PD‐L1 immune checkpoint blocker
Wang, Z., & Wu, X. (2020) · Cancer Medicine · doi:10.1002/cam4.3410 · Cited by 195
Resistance mechanisms to immune checkpoint inhibitors: updated insights
Alsaafeen, B. H., Ali, B. R., & Elkord, E. (2025) · Molecular Cancer · doi:10.1186/s12943-024-02212-7 · Cited by 191
Chowdhury, P. S., Chamoto, K., & Honjo, T. (2018) · Journal of Internal Medicine · doi:10.1111/joim.12708 · Cited by 191
Emerging concepts in PD-1 checkpoint biology
Pauken, K. E., Torchia, J. A., Chaudhri, A., Sharpe, A. H., & Freeman, G. J. (2021) · Seminars in Immunology · doi:10.1016/j.smim.2021.101480 · Cited by 191
Magnetic nanoparticles for cancer theranostics: Advances and prospects
Li, X., Li, W., Wang, M., & Liao, Z. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.042 · Cited by 194
Targeting Wnt/β-Catenin Signaling for Cancer Immunotherapy
Wang, B., Tian, T., Kalland, K.-H., Ke, X., & Qu, Y. (2018) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2018.03.008 · Cited by 192
Kotliarov, Y., Sparks, R., Martins, A. J., Mulè, M. P., Lu, Y., Goswami, M., Kardava, L., Banchereau, R., Pascual, V., Biancotto, A., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0769-8 · Cited by 190
Truxova, I., Kasikova, L., Hensler, M., Skapa, P., Laco, J., Pecen, L., Belicova, L., Praznovec, I., Halaska, M. J., Brtnicky, T., et al. (2018) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-018-0446-3 · Cited by 191
Immunogenomic Landscape of Hematological Malignancies
Dufva, O., Pölönen, P., Brück, O., Keränen, M. A. I., Klievink, J., Mehtonen, J., Huuhtanen, J., Kumar, A., Malani, D., Siitonen, S., et al. (2020) · Cancer Cell · doi:10.1016/j.ccell.2020.06.002 · Cited by 190
Ravi, A., Hellmann, M. D., Arniella, M. B., Holton, M., Freeman, S. S., Naranbhai, V., Stewart, C., Leshchiner, I., Kim, J., Akiyama, Y., et al. (2023) · Nature Genetics · doi:10.1038/s41588-023-01355-5 · Cited by 188
Ferris, R. L., Lenz, H.-J., Trotta, A. M., García-Foncillas, J., Schulten, J., Audhuy, F., Merlano, M., & Milano, G. (2018) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2017.11.008 · Cited by 190
Li, M., Liu, F., Zhang, F., Zhou, W., Jiang, X., Yang, Y., Qu, K., Wang, Y., Ma, Q., Wang, T., et al. (2019) · Gut · doi:10.1136/gutjnl-2018-316039 · Cited by 188
Nakao, S., Arai, Y., Tasaki, M., Yamashita, M., Murakami, R., Kawase, T., Amino, N., Nakatake, M., Kurosaki, H., Mori, M., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aax7992 · Cited by 187
Shao, W., Yang, Z., Fu, Y., Zheng, L., Liu, F., Chai, L., & Jia, J. (2021) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2021.676485 · Cited by 190
“Cluster 1 was classified as an immune-inflamed phenotype while cluster 2 was classified as an immune-excluded phenotype (Chen and Mellman, 2017).”
BackgroundNixon, B. G., Kuo, F., Ji, L., Liu, M., Capistrano, K., Do, M., Franklin, R. A., Wu, X., Kansler, E. R., Srivastava, R. M., et al. (2022) · Immunity · doi:10.1016/j.immuni.2022.10.002 · Cited by 187
Burugu, S., Gao, D., Leung, S., Chia, S. K., & Nielsen, T. O. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx557 · Cited by 189
Donlon, N. E., Power, R., Hayes, C., Reynolds, J. V., & Lysaght, J. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.12.045 · Cited by 189
“meostasis known as immune checkpoints and reinvigorate exhausted CD8 T cells [5].”
BackgroundInhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression
Segovia, C., San José-Enériz, E., Munera-Maravilla, E., Martínez-Fernández, M., Garate, L., Miranda, E., Vilas-Zornoza, A., Lodewijk, I., Rubio, C., Segrelles, C., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0499-y · Cited by 186
The Skp2 Pathway: A Critical Target for Cancer Therapy
Cai, Z., Moten, A., Peng, D., Hsu, C.-C., Pan, B.-S., Manne, R., Li, H.-Y., & Lin, H.-K. (2020) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.01.013 · Cited by 186
Bioengineered nanogels for cancer immunotherapy
Ma, X., Li, S.-J., Liu, Y., Zhang, T., Xue, P., Kang, Y., Sun, Z.-J., & Xu, Z. (2022) · Chemical Society Reviews · doi:10.1039/d2cs00247g · Cited by 185
Nguyen, M., De Ninno, A., Mencattini, A., Mermet-Meillon, F., Fornabaio, G., Evans, S. S., Cossutta, M., Khira, Y., Han, W., Sirven, P., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2018.12.015 · Cited by 184
“In the era of emerging immunotherapies for cancer (Chen and Mellman, 2017), the technological development of standardized tumors-on-chip could be very valuable to study new oncoimmunotherapies, to increase their efficacy, and to understand the mechanisms of resistance.”
BackgroundThe Promise of Neoadjuvant Immunotherapy and Surgery for Cancer Treatment
O'Donnell, J. S., Hoefsmit, E. P., Smyth, M. J., Blank, C. U., & Teng, M. W. L. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-2641 · Cited by 182
Immune checkpoint inhibitors: Key trials and an emerging role in breast cancer
Gaynor, N., Crown, J., & Collins, D. M. (2022) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2020.06.016 · Cited by 182
Immunobiology of high-grade serous ovarian cancer: lessons for clinical translation
Kandalaft, L. E., Dangaj Laniti, D., & Coukos, G. (2022) · Nature Reviews Cancer · doi:10.1038/s41568-022-00503-z · Cited by 180
Gut microbiome modulates efficacy of immune checkpoint inhibitors
Yi, M., Yu, S., Qin, S., Liu, Q., Xu, H., Zhao, W., Chu, Q., & Wu, K. (2018) · Journal of Hematology & Oncology · doi:10.1186/s13045-018-0592-6 · Cited by 179
“summarize pathways involving in ICIs treatments, which could be understood as the threshold to overcome for immune response to neoantigen [100].”
Background
Metadata
- Authors
- Chen, D. S., & Mellman, I.
- Affiliations
- Genentech (US)
- Corresponding author
- Mellman, Ira
- Venue
- Nature
- Published
- 2017-01
- Volume
- 541
- Issue
- 7637
- Pages
- 321-330
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2578528809
- Cited by
- 5,352
- References
- 121
- Citations by year
- 2026: 524 · 2025: 527 · 2024: 626 · 2023: 708 · 2022: 848 · 2021: 681 · 2020: 582 · 2019: 386 · 2018: 335 · 2017: 131
- FWCI
- 41.37
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- RePEc: Research Papers in Economics (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- antitumor immunity, cancer-immunity cycle, immunotherapy response, CTLA-4, PD-1/PD-L1, immune checkpoint inhibitors, tumor immune microenvironment, immunological profile, predictive biomarkers, durable response
- MeSH terms
- Animals, Humans, Immunologic Memory, Immunotherapy, Inflammation, Neoplasms, T-Lymphocytes, Genome, Human, Tumor Escape, Epigenesis, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.